Advertisement

Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials

      Highlights

      • SGLT-2 inhibitors stimulate ketone reabsorption, increasing the risk of ketoacidosis.
      • Ketoacidosis with SGLT2 inhibitors is a relevant acidosis with mild hyperglycemia.
      • If the drug is properly prescribed, the risk of DKA is negligible in type 2 diabetes.

      Abstract

      Aims

      Diabetic ketoacidosis (DKA) associated with SGLT-2 inhibitors (SGLT-2i) is a possible adverse event. In fact, SGLT-2i are capable of stimulating the release of glucagon and ketone re-absorption in the renal tubuli, thus increasing the concentration of ketone bodies.

      Methods

      A Medline search for SGLT2i (dapagliflozin, empagliflozin, canagliflozin, ipragliflozin, ertugliflozin, luseogliflozin) was performed, collecting all randomized trials with a duration of treatment ≥ 12 weeks, enrolling patients with type 2 diabetes, and comparing a SGLT2i with placebo or other comparators. The principal outcome was the effect of SGLT2i on ketoacidosis as serious adverse event.

      Results

      Out of 72 trials reporting information on DKA, 9 reported at least one event of ketoacidosis; those eight trials enrolled 10,157 and 5396 in SGLT-2 inhibitors and comparator groups, respectively. No signal of increased risk for ketoacidosis was observed for SGLT2 inhibitors as a class (MH-OR [95% CI] 1.14 [0.45–2.88], p = 0.78) or as individual molecule. The sensitivity analysis with continuity correction (inputing one event each in drug and comparator arms of each trial with zero events) suggested a reduced incidence of ketoacidosis in patients treated with SGLT-2 inhibitors (MH-OR 0.65 [0.47–0.90]; p = 0.01).

      Conclusions

      The results of clinical trials summarized in the present meta-analysis reassure us that, when the drug is properly prescribed, the risk of DKA is negligible.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hemmingsen B.
        • Krogh J.
        • Metzendorf M.I.
        • Richter B.
        Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
        Cochrane Database Syst Rev. 2016; (Epub-ahead of print)
        • Scheen A.J.
        Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
        Drugs. 2015; 75: 33-59
        • Zinman B.
        • Wanner C.
        • Lachin J.M.
        • Fitchett D.
        • Bluhmki E.
        • Hantel S.
        • et al.
        Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
        N Engl J Med. 2015; 373: 2117-2128
        • Wu J.H.
        • Foote C.
        • Blomster J.
        • Toyama T.
        • Perkovic V.
        • Sundström J.
        • et al.
        Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
        Lancet Diabetes Endocrinol. 2016; 4: 411-419
        • Burke K.R.
        • et al.
        SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature.
        Pharmacotherapy. 2017; 37: 187-194
      1. Food and Drug Administration. Safety Alert on Canagliflozin, issued on Oct 10th, 2015. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm461876.htm. Last accessed on 3rd August, 2016.

        • Peters A.L.
        • Buschur E.O.
        • Buse J.B.
        • Cohan P.
        • Diner J.C.
        • Hirsch I.B.
        Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition.
        Diabetes Care. 2015; 38: 1687-1693
        • Qiu H.
        • Novikov A.
        • Vallon V.
        Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives.
        Diabetes Metab Res Rev. 2017; ([Epub ahead of print])
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        Ann Intern Med. 2009; 151: 264-269
        • Bode B.
        • Stenlöf K.
        • Sullivan D.
        • Fung A.
        • Usiskin K.
        Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
        Hosp Pract. 1995; 2013: 72-84
      2. https://clinicaltrials.gov/ct2/show/NCT01032629?term=nct01032629&rank=1. Last accessed on 3rd August, 2016.

        • Lavalle-González F.J.
        • Eliaschewitz F.G.
        • Cerdas S.
        • Chacon Mdel P.
        • Tong C.
        • Alba M.
        Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
        Curr Med Res Opin. 2016; 32: 427-439
        • Wilding J.P.
        • Woo V.
        • Rohwedder K.
        • Sugg J.
        • Parikh S.
        • Dapagliflozin 006 Study Group
        Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
        Diabetes Obes Metab. 2014; 16: 124-136
        • Barnett A.H.
        • Mithal A.
        • Manassie J.
        • Jones R.
        • Rattunde H.
        • Woerle H.J.
        • et al.
        Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
        Lancet Diabetes Endocrinol. 2014; 2: 369-384
        • Rosenstock J.
        • Jelaska A.
        • Frappin G.
        • Salsali A.
        • Kim G.
        • Woerle H.J.
        • et al.
        Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
        Diabetes Care. 2014; 37: 1815-1823
        • Tikkanen I.
        • Narko K.
        • Zeller C.
        • Green A.
        • Salsali A.
        • Broedl U.C.
        • et al.
        Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
        Diabetes Care. 2015; 38: 420-428
      3. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Last accessed on 3rd August, 2016.

        • Taylor S.I.
        • Blau J.E.
        • Rother K.I.
        SGLT2 inhibitors may predispose to ketoacidosis.
        J Clin Endocrinol Metab. 2015; 100: 2849-2852
        • Tang H.
        • Li D.
        • Wang T.
        • Zhai S.
        • Song Y.
        Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials.
        Diabetes Care. 2016; 39: e123-e124
      4. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Last accessed on 3rd August, 2016.

        • Rosenstock G.
        • Ferrannini E.
        Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors.
        Diabetes Care. 2015; 38: 1638-1642